

Ref: FOI/GS/ID 6521

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

29 January 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Rheumatology.

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- a. Abatacept [Orencia]*
- b. Adalimumab [Humira]*
- c. Adalimumab Biosimilars*
- d. Apremilast [Otezla]*
- e. Baricitinib [Olumiant]*
- f. Certolizumab [Cimzia]*
- g. Etanercept [Enbrel]*
- h. Etanercept Biosimilars*
- i. Filgotinib [Jyseleca]*
- j. Golimumab [Simponi]*
- k. Infliximab [Remicade]*
- l. Infliximab Biosimilars*
- m. Ixekizumab [Taltz]*
- n. Rituximab [MabThera]*
- o. Rituximab Biosimilars*
- p. Sarilumab [Kevzara]*
- q. Secukinumab [Cosentyx]*
- r. Tocilizumab [Ro Actemra]*
- s. Tofacitinib [Xeljanz]*
- t. Upadacitinib [Rinvoq]*
- u. Ustekinumab [Stelara]*

Q2. Could you please provide the numbers of patients treated for Ankylosing Spondylitis ONLY in the last 3 months with the following drugs:

- a. *Adalimumab [Humira]*
- b. *Adalimumab Biosimilars*
- c. *Certolizumab [Cimzia]*
- d. *Etanercept [Enbrel]*
- e. *Etanercept Biosimilars*
- f. *Golimumab [Simponi]*
- g. *Infliximab [Remicade]*
- h. *Infliximab Biosimilars*
- i. *Ixekizumab [Taltz]*
- j. *Secukinumab [Cosentyx]*

Trust response:

Figures are for patients who had invoiced items between OCT and DEC 2020 inclusive.

Q1.

- a. 73
- b. 92
- c. 239
- d. 1
- e. 18
- f. 33
- g. 26
- h. 205
- i. NOT USED
- j. 108
- k. 12
- l. 34
- m. 1
- n. 4
- o. 47
- p. 0
- q. 74
- r. 28
- s. 24
- t. NOT USED
- u. 6

Q2.

- a. 0
- b. 0
- c. 7
- d. 2
- e. 32
- f. 29
- g. 3
- h. 12
- i. 0
- j. 24